New drug hope for fatty liver in diabetes patients?
NCT ID NCT07198516
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This early-stage study tests whether a drug called Henggliejin can improve fatty liver in people with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD). About 149 adults will take the drug for 48 weeks to see if it reduces liver scarring. The goal is to find a safer way to manage liver health in this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.